Table 1.
Summary of patients with endophthalmitis following intravitreal injection of anti-VEGF agent
| Patient | Diagnosis | Medication | Pre-injection VA | VA at presentation | Days to presentation | Treatment | Culture results | Continued anti-VEGF? | Final VA | Length of follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BRVO/CME | Bevacizumab | 20/50 | CF | 2 | Tap/inject | CONS | N | 20/40 − 1 | 12 |
| 2 | BRVO/CME | Bevacizumab | 20/100 | HM | 3 | Tap/inject, then PPV | CONS | Y | 20/125 | 23 |
| 3 | CRVO/CME | Bevacizumab | 20/40 | CF | 15 | PPV | CONS | N | HM | 26 |
| 4 | DME | Bevacizumab | 20/60 | CF | 4 | Tap/inject | CONS | Y | 20/80 | 22 |
| 5 | NVAMD | Bevacizumab | 20/40 − 2 | 20/80 | 3 | Tap/inject | CONS | Y | 20/80 | 25 |
| 6 | Radiation retinopathy s/p plaque therapy for MM | Ranibizumab | 20/200 | HM | 3 | Tap/inject | CONS | Y | 20/250 | 11 |
| 7 | NVAMD | Ranibizumab | 20/100 | CF | 7 | Tap/inject, then PPV | CONS | N | 20/160, ph 20/125 | 13 |
| 8 | DME | Bevacizumab | ? (elsewhere) | HM | 4 | Tap/inject, then PPV | CONS | Y | 20/40 | 10 |
| 9 | CRVO/CME | Ranibizumab | 20/63 | CF | 3 | Tap/inject | Corynebacterium | Y | 20/80 | 23 |
| 10 | MC/CNV | Ranibizumab | 20/25 | HM | 1 | Tap/inject, then PPV | Strep viridans, Neisseria | Y | 20/160 | 16 |
| 11 | NVAMD | Bevacizumab | ? (elsewhere) | 20/400 | 4 | Tap/inject, then PPV | E. coli, Enterobacter cloacae | N | 20/50 + 2 | 4 |
| 12 | NVAMD | Bevacizumab | 20/126 | 20/100 | 4 | Tap/inject, then PPV | Lactococcus garvieae, CONS | Y | 20/40 | 18 |
| 13 | NVAMD | Bevacizumab | 20/80 | CF | 5 | Tap/inject | No growth | Y | 20/150 | 22 |
| 14 | CRVO/CME | Bevacizumab | 20/250 − 3 | HM | 4 | Tap/inject | No growth | N | HM | 4 |
| 15 | NVAMD | Ranibizumab | 20/200 − 2 | 1/200 | 4 | Tap/inject | No growth | N | CF | 21 |
| 16 | CRVO/CME | Ranibizumab | ? | 20/100 | 3 | Tap/inject | No growth | Y | ? | 1 |
Summary of patients with endophthalmitis following intravitreal injection of anti-VEGF agent
Abbreviations: VA visual acuity, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, CME cystoid macular edema, DME diabetic macular edema, NVAMD neovascular age-related macular degeneration, MC multifocal choroiditis, CNV choroidal neovascularization, MM malignant choroidal melanoma, CF counting fingers, HM hand motions, PPV pars plana vitrectomy, CONS coagulase-negative Staphylococcus